Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYGL | P06737 | 7/20 | 0.44 |
| ▸ | F11 | P03951 | 4/20 | 0.39 |
| ▸ | MMP9 | P14780 | 1/20 | 0.39 |
| ▸ | MMP8 | P22894 | 1/20 | 0.39 |
| ▸ | MMP14 | P50281 | 1/20 | 0.39 |
| ▸ | CBX7 | O95931 | 1/20 | 0.38 |
| ▸ | CDYL | Q9Y232 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2497643 | 0.93 | PYGL (0.39) | PYGLCBX7CDYLKMT2A | |
| SCHEMBL2498324 | 0.93 | MMP9 (0.44) | MMP9MMP8PSMB5 | |
| SCHEMBL2494983 | 0.91 | NPC1 (0.39) | PYGLF11CBX7CDYL | |
| SCHEMBL2492829 | 0.90 | KMT2A (0.40) | PYGLCBX7CDYLKMT2A | |
| SCHEMBL2496408 | 0.90 | CBX7 (0.40) | CBX7CDYLKMT2A | |
| SCHEMBL2501794 | 0.88 | CBX7 (0.39) | CBX7CDYLKMT2APSMB5 | |
| SCHEMBL2498534 | 0.88 | CBX7 (0.39) | PYGLCBX7CDYLKMT2A | |
| SCHEMBL2498800 | 0.88 | CBX7 (0.38) | PYGLCBX7CDYLKMT2APSMB5 | |
| SCHEMBL2496913 | 0.87 | SNRNP200 (0.39) | F11CBX7CDYLKMT2A | |
| SCHEMBL2499409 | 0.87 | CBX7 (0.38) | CBX7CDYLKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8030499-B2 | 1,3-dihydro-2H-indole-2-one compound and pyrrolidine-2-one compound fused with aromatic heterocycle | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2011-10-04 | — | — | US | disclosed |
| US-20080318923-A1 | 1,3-Dihydro-2H-Indole-2-One Compound and Pyrrolidine-2-One Compound Fused With Aromatic Heterocycle | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2008-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080318923-A1 | 1,3-Dihydro-2H-Indole-2-One Compound and Pyrrolidine-2-One Compound Fused With Aromatic Heterocycle | AVPR1B, AVPR1A, AVPR2 | PYGL 2655/4885F11 3195/4885MMP9 999/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.